Guggenheim Initiates Coverage On Zenas BioPharma with Buy Rating, Announces Price Target of $45

Benzinga · 10/08 09:46
Guggenheim analyst Yatin Suneja initiates coverage on Zenas BioPharma (NASDAQ:ZBIO) with a Buy rating and announces Price Target of $45.